Evidence map›Paper›PMID 40461859›Full record

ArticleCell biology and toxicology2025

Exosomal POU5 F1 derived from TNBC promotes cancer progression by regulating M2 macrophage polarization via inhibiting TRAF6 ubiquitination and activating AKT in macrophage.

Yimeng Chai, Yao Shi

Abstract read
In one paragraph

Article in Cell biology and toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yimeng ChaiDepartment of Breast Surgery, the First Hospital of China Medical University, 155 Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China.
Yao ShiDepartment of Breast Surgery, the First Hospital of China Medical University, 155 Nanjing Street, Heping District, Shenyang, 110001, Liaoning, China. maliyajimi@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exosomes are pivotal in triple-negative breast cancer (TNBC) development, and accumulating evidence underscores their potential as therapeutic targets and diagnostic indicators. In this study, we revealed a significant enrichment of the POU domain, class 5, transcription factor 1 (POU5F1) in TNBC cells-derived exosomes. Functionally, silencing endogenous POU5F1 in TNBC cells substantially inhibited their aggressive phenotypes. Moreover, exosomes derived from TNBC cells contributed to macrophage M2 polarization by transferring POU5F1 to the recipient macrophages. Mechanistically, POU5F1 within these exosomes prevented the tumor necrosis factor receptor-associated factor 6 (TRAF6) degradation in macrophages, thereby activating the protein kinase B (AKT) signaling cascade and driving M2 polarization. Furthermore, in vivo experiments provided evidence that POU5F1 knockdown significantly reduced tumor growth and macrophage M2 polarization in a mouse model of TNBC cells by modulating the TRAF6/AKT signaling axis. Our study concludes that POU5F1 in TNBC cells-derived exosomes is vital for promoting macrophage M2 polarization by inhibiting TRAF6 ubiquitination and activating AKT signaling, thereby contributing to TNBC progression.

Indexed as

ExosomesMacrophagesProto-Oncogene Proteins c-aktTNF Receptor-Associated Factor 6Triple Negative Breast NeoplasmsAnimalsCell Line, TumorDisease ProgressionFemaleHumansIntracellular Signaling Peptides and ProteinsMiceMice, Inbred BALB CSignal TransductionUbiquitinationIntracellular Signaling Peptides and ProteinsProto-Oncogene Proteins c-aktTifab protein, humanTNF Receptor-Associated Factor 6ExosomesMacrophagePolarizationPOU5 F1TNBCUbiquitination

Identifiers

PMID40461859
PMCPMC12134049

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.